Smith C J, Volkert W A, Hoffman T J
Radiopharmaceutical Sciences Institute, University of Missouri, Columbia, MO 65211, USA.
Nucl Med Biol. 2003 Nov;30(8):861-8. doi: 10.1016/s0969-8051(03)00116-1.
The gastrin releasing peptide (GRP) receptor is becoming an increasingly attractive target for development of new radiolabeled peptides with diagnostic and therapeutic potential. The attractiveness of the GRP receptor as a target is based upon the functional expression of GRP receptors in several tumors of neuroendocrine origin including prostate, breast, and small cell lung cancer. This concise review outlines some of the efforts currently underway to develop new GRP receptor specific radiopharmaceuticals by employing a variety of radiometal chelation systems.
胃泌素释放肽（GRP）受体正日益成为开发具有诊断和治疗潜力的新型放射性标记肽的一个有吸引力的靶点。GRP受体作为靶点的吸引力基于其在包括前列腺癌、乳腺癌和小细胞肺癌在内的几种神经内分泌源性肿瘤中的功能性表达。这篇简短的综述概述了目前正在进行的一些努力，即通过采用多种放射性金属螯合系统来开发新的GRP受体特异性放射性药物。
